These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment of systemic lupus erythematosus (SLE) with immunosuppressive drugs 1: An analysis of immunologic data. Cruchaud A; Pometta D; Rousso C Helv Med Acta; 1967 Dec; 34(1):5-22. PubMed ID: 4173836 [No Abstract] [Full Text] [Related]
4. Immunopathologic studies of systemic lupus erythematosus (SLE). I. Tissue-bound immunoglobulins in relation to serum antinuclear immunoglobulins in systemic lupus and in chronic liver disease with LE cell factor. Svec KH; Blair JD; Kaplan MH J Clin Invest; 1967 Apr; 46(4):558-68. PubMed ID: 4164259 [TBL] [Abstract][Full Text] [Related]
5. [Antinuclear factor, phenomena of the LE cells and complement in systemic erythematosus]. Okuda M Nihon Rinsho; 1968 Dec; 26(12):3438-48. PubMed ID: 4181083 [No Abstract] [Full Text] [Related]
7. [Intervention of heparin in immunological phenomena: reversibility of the nuclear antigen and antinuclear antibody reaction in systemic lupus erythematosus]. Bardare M; Menghi P Boll Soc Ital Biol Sper; 1965 Jul; 41(13):713-5. PubMed ID: 4164914 [No Abstract] [Full Text] [Related]
8. Intracytoplasmic inclusions of immunoglobulins in rheumatoid arthritis and other diseases. Vaughan JH; Barrnett EV; Sobel MV; Jacox RF Arthritis Rheum; 1968 Apr; 11(2):125-34. PubMed ID: 4171444 [No Abstract] [Full Text] [Related]
11. Anti-nuclear factors in rheumatoid arthritis, systemic lupus erythematosus and other diseases. Re-evaluation of the nucleoprotein complement fixation technique and anti-complementary activity. Onodera S; Schubart AF; Ewald RW; Heuckenkamp PU J Chronic Dis; 1966; 19(11):1133-44. PubMed ID: 5297998 [No Abstract] [Full Text] [Related]
12. [Determination of the immunoglobulin type of complement fixing and non-fixing anti-nuclear factors]. Peltier AP; Strejcek G Rev Fr Etud Clin Biol; 1969 Oct; 14(8):787-95. PubMed ID: 4189485 [No Abstract] [Full Text] [Related]
13. Specificity and reactivity of cytoplasmic and nucleolar antibody in SLE sera. Watanabe N; Fisher HM; Epstein WV Arthritis Rheum; 1969 Jun; 12(3):173-80. PubMed ID: 4182395 [No Abstract] [Full Text] [Related]
14. [On the problem of immunobiologic relations between lupus erythematosus disseminatus and progressive scleroderma]. Meyer zum Büschenfelde ; Talke H; Holzmann H Arch Klin Exp Dermatol; 1967; 228(4):396-407. PubMed ID: 4171697 [No Abstract] [Full Text] [Related]
15. [Relationship between serum complement titer (CH50), immune adherence (IA), beta-1-A-globulin, transferrin, IgA, IgM and IgG in SLE]. Ishikawa Y Arerugi; 1969 Dec; 18(12):966-72. PubMed ID: 4189140 [No Abstract] [Full Text] [Related]
16. Mechanisms of renal injury in systemic lupus erythematosus. Koffler D; Kunkel HG Am J Med; 1968 Aug; 45(2):165-9. PubMed ID: 4174390 [No Abstract] [Full Text] [Related]
17. Cold-insoluble complexes and complement levels in systemic lupus erythematosus. Stastny P; Ziff M N Engl J Med; 1969 Jun; 280(25):1376-81. PubMed ID: 4181609 [No Abstract] [Full Text] [Related]
18. [Lupus erythematosus disseminatus: model of an autoimmune disease?]. Mueller-Eckhardt C Dtsch Med Wochenschr; 1969 May; 94(19):1024-31. PubMed ID: 4181103 [No Abstract] [Full Text] [Related]
19. [Whole serum complement in kidney diseases and systemic lupus erythematosus]. Stein G; Stelzner A; Tanner E Z Gesamte Inn Med; 1973 Aug; 28(16):469-76. PubMed ID: 4129087 [No Abstract] [Full Text] [Related]
20. [Current viewpoints on the pathogenesis of lupus erythematosus]. Sönnichsen N; Haustein UF; Barthelmes H Z Arztl Fortbild (Jena); 1971 Jun; 65(12):581-5. PubMed ID: 4939579 [No Abstract] [Full Text] [Related] [Next] [New Search]